| The myth of the biotech revolution: An assessment of technological, clinical and organisational change MM Hopkins, PA Martin, P Nightingale, A Kraft, S Mahdi Research policy 36 (4), 566-589, 2007 | 374 | 2007 |
| Big Pharma, little science?: A bibliometric perspective on Big Pharma's R&D decline I Rafols, MM Hopkins, J Hoekman, J Siepel, A O'Hare, ... Technological forecasting and social change 81, 22-38, 2014 | 213 | 2014 |
| Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe ME van den Akker-van Marle, D Gurwitz, SB Detmar, CM Enzing, ... Pharmacogenomics 7 (5), 783-792, 2006 | 162 | 2006 |
| From funding gaps to thin markets: UK government support for early-stage venture capital P Nightingale, G Murray, M Cowling, C Baden-Fuller, C Mason, J Siepel, ... National Endowment for Science, Technology and the Arts, 2009 | 111 | 2009 |
| Putting pharmacogenetics into practice MM Hopkins, D Ibarreta, S Gaisser, CM Enzing, J Ryan, PA Martin, ... Nature biotechnology 24 (4), 403-410, 2006 | 108 | 2006 |
| Strategic intelligence on emerging technologies: Scientometric overlay mapping D Rotolo, I Rafols, MM Hopkins, L Leydesdorff Journal of the Association for Information Science and Technology 68 (1 …, 2017 | 91 | 2017 |
| Funding data from publication acknowledgments: Coverage, uses, and limitations N Grassano, D Rotolo, J Hutton, F Lang, MM Hopkins Journal of the Association for Information Science and Technology 68 (4 …, 2017 | 89 | 2017 |
| The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies A Woelderink, D Ibarreta, MM Hopkins, E Rodriguez-Cerezo The pharmacogenomics journal 6 (1), 3-7, 2006 | 87 | 2006 |
| Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980–2009 MM Hopkins, PA Crane, P Nightingale, C Baden-Fuller Industrial and Corporate Change 22 (4), 903-952, 2013 | 73 | 2013 |
| Generative and degenerative interactions: positive and negative dynamics of open, user‐centric innovation in technology and engineering consultancies MM Hopkins, J Tidd, P Nightingale, R Miller R&d Management 41 (1), 44-60, 2011 | 73 | 2011 |
| Pharmacogenetics in Europe: barriers and opportunities D Gurwitz, E Zika, MM Hopkins, S Gaisser, D Ibarreta Public Health Genomics 12 (3), 134-141, 2009 | 69 | 2009 |
| Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK MM Hopkins, P Nightingale Research policy 35 (3), 355-374, 2006 | 64 | 2006 |
| The hidden research system: The evolution of cytogenetic testing in the national health service MM Hopkins Science as culture 15 (3), 253-276, 2006 | 63 | 2006 |
| DNA patenting: the end of an era? MM Hopkins, S Mahdi, P Patel, SM Thomas Nature biotechnology 25 (2), 185-187, 2007 | 62 | 2007 |
| A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA S Hogarth, MM Hopkins, V Rodriguez Sociology of health & illness 34 (2), 234-250, 2012 | 59 | 2012 |
| Towards a method for evaluating technological expectations: Revealing uncertainty in gene silencing technology discourse JJ Sung, MM Hopkins Technology Analysis & Strategic Management 18 (3-4), 345-359, 2006 | 49 | 2006 |
| Projects, project capabilities and project organizations P Nightingale, C Baden-Fuller, MM Hopkins Project-based organizing and strategic management, 215-234, 2011 | 40 | 2011 |
| Science, the State and the City: Britain's Struggle to Succeed in Biotechnology G Owen, MM Hopkins Oxford University Press, 2016 | 37 | 2016 |
| Shares in the human genome—the future of patenting DNA SM Thomas, MM Hopkins, M Brady nature biotechnology 20 (12), 1185-1188, 2002 | 36 | 2002 |
| The phantom menace of gene patents S Gaisser, MM Hopkins, K Liddell, E Zika, D Ibarreta Nature 458 (7237), 407-408, 2009 | 34 | 2009 |
Paul NightingaleSussexVerified email at sussex.ac.uk
